Retatrutide Phase 3 (TRIUMPH Program): What the Trials Are Designed to Answer

The 2023 NEJM Phase 2 publication was widely reported as a breakthrough — and the 24.2% mean weight reduction at 48 weeks in the highest dose cohort was genuinely exceptional. But Phase 2 success, however dramatic, cannot substitute for Phase 3 confirmation. Understanding why requires understanding what Phase 2 was and was not designed to show.

The retatrutide Phase 2 trial enrolled 338 participants at 25 US sites. It was a dose-finding study, designed to establish which doses produced meaningful efficacy and what dose-limiting adverse events occurred at each level. At this sample size, it was not powered to detect rare adverse events (those occurring in less than 1% of subjects), long-term safety signals, or outcomes in populations not represented in the 25-site US cohort. It could not generate cardiovascular outcomes data, because 338 participants followed for 48 weeks produces essentially no cardiovascular events in a population selected for the absence of recent major cardiovascular disease.

Phase 3 exists to answer what Phase 2 cannot: Does the efficacy hold in a broader, more diverse population? What is the long-term safety profile at 2+ years? Does the metabolic improvement translate to reduced cardiovascular risk? What happens to weight after treatment discontinuation? These questions require sample sizes of thousands rather than hundreds, trial durations of years rather than months, and deliberately diverse enrollment that Phase 2 does not require.

The TRIUMPH program for retatrutide is structured across multiple concurrent trials, each designed to address a specific regulatory and scientific question that the Phase 2 data could not resolve. This multi-trial architecture mirrors the programs run for semaglutide (STEP program) and tirzepatide (SURMOUNT program), both of which required 5-6 individual trials to assemble the regulatory package for FDA approval.

TRIUMPH-1 (Obesity, no T2DM): The registrational obesity trial — the direct successor to Phase 2 in the population most represented in that study. Enrollment of adults with obesity (BMI ≥30) or overweight with at least one weight-related comorbidity, without type 2 diabetes. Primary endpoint: percent change from baseline body weight at 72 weeks. This is the landmark trial, designed to show the regulatory-quality evidence of sustained weight reduction that the FDA requires for obesity drug approval.

TRIUMPH-2 (Obesity with Type 2 Diabetes): A separate trial in patients with both obesity and established type 2 diabetes. This is a required separation from TRIUMPH-1 because T2DM patients have a different metabolic profile, different baseline characteristics, and require separate benefit-risk evaluation. The co-primary endpoints include both body weight reduction and HbA1c reduction — the two regulatory thresholds for metabolic drug approval in this population.

TRIUMPH-CVOT (Cardiovascular Outcomes): The cardiovascular outcomes trial that is required for any obesity drug seeking FDA approval following the 2012 FDA guidance and real-world precedents set by semaglutide and tirzepatide CVOTs. This trial will enroll patients at elevated cardiovascular risk and follow them for multiple years, powered to demonstrate non-inferiority (and potentially superiority) for major adverse cardiovascular events (MACE) — the composite of CV death, non-fatal MI, and non-fatal stroke.

The primary endpoints chosen for Phase 3 differ meaningfully from the Phase 2 endpoints, and these differences are scientifically important.

Phase 2 primary endpoint: percent change from baseline body weight at 48 weeks. This is a surrogate endpoint — it measures something that is expected to correlate with health outcomes, but it is not itself a clinical outcome. It does not tell us whether the weight loss translates to reduced diabetes risk, reduced cardiovascular events, improved quality of life, or reduced mortality.

Phase 3 primary endpoint: sustained percent change from baseline body weight at 72 weeks — a longer duration, providing more information about plateau and maintenance. Secondary endpoints in TRIUMPH include: proportion achieving ≥5%, ≥10%, ≥15%, ≥20% weight loss (capturing the distribution of response across the population), waist circumference (visceral fat as distinct from total weight), blood pressure, fasting glucose, HbA1c, lipid panel changes, and patient-reported outcome measures.

The CVOT endpoints go further: they will provide the first direct evidence of whether retatrutide reduces actual cardiovascular events — not just the surrogate markers like blood pressure and LDL-C that are associated with cardiovascular risk. This is the question that ultimately determines whether retatrutide offers not just superior weight loss, but superior health outcomes relative to the approved alternatives.

One of the most scientifically significant features of the Phase 2 retatrutide data was the shape of the weight loss curves. In the high-dose cohorts, the weight loss trajectories had not plateaued by week 48 — the curves were still declining at the trial endpoint. This is different from what was observed in semaglutide and tirzepatide Phase 3 trials, where weight loss curves showed clear plateaus by 52-68 weeks.

The absence of a plateau in retatrutide Phase 2 is consistent with the glucagon receptor component contributing ongoing energy expenditure increases that compound over time — the thermogenic mechanism may require longer to produce its full effect than the appetite suppression component alone. If this interpretation is correct, Phase 3 data at 72 weeks may show mean weight reduction exceeding 24.2%, potentially reaching 26-30% in the highest-responding populations.

This is a key research question that Phase 3 will directly answer. The semaglutide STEP trials showed that extending treatment from 68 to 104 weeks produced modest additional weight loss after the plateau at ~68 weeks. If retatrutide Phase 3 data shows continued weight loss at 72 weeks without a plateau, it would indicate that the triple agonism mechanism has a longer time-to-maximal-effect than the single and dual agonist mechanisms — a scientifically important distinction with implications for dosing duration guidelines.

The Phase 2 retatrutide trial enrolled 338 adults at 25 US sites, with the inclusion criteria of BMI 27-50 and HbA1c below 10% if diabetic. This is a relatively homogeneous population — predominantly US, predominantly English-speaking, with access to tertiary research centers and sufficient motivation to complete a 53-week double-blind trial.

FDA approval requires demonstrating efficacy across the full spectrum of the indicated population. TRIUMPH Phase 3 enrollment criteria are broader and geographically more diverse, including trial sites across North America, Europe, Latin America, and Asia-Pacific. The racial and ethnic diversity requirements for Phase 3 are substantially higher than Phase 2 — drugs approved in 2024 are expected to show efficacy in populations that reflect the actual demographics of people with obesity globally.

This diversity matters scientifically. GLP-1 receptor density, GIP receptor polymorphisms, and glucagon receptor variants differ across ethnic groups in ways that could affect drug response. Phase 3 data in more diverse populations will provide the first evidence of whether retatrutide's efficacy generalizes across ethnic groups or whether, like some other metabolic drugs, response rates are meaningfully different in specific populations.

The T2DM cohort in TRIUMPH-2 also represents a population not dominant in Phase 2. Patients with established T2DM have different baseline insulin secretion capacity, different receptor sensitivity profiles, and potentially different weight loss trajectories in response to GLP-1/GIP/glucagon triple agonism. TRIUMPH-2 data will be the first direct characterization of retatrutide in this critical population.

At 338 participants followed for 48-53 weeks, the Phase 2 retatrutide trial was designed to detect common adverse events (those occurring in more than 5% of subjects) but could not detect rare adverse events (less than 1%) or adverse events that emerge only after 12+ months of continuous treatment.

Phase 3 TRIUMPH trials, with thousands of participants followed for 72+ weeks, will provide the first meaningful data on several safety questions. Thyroid C-cell effects: GLP-1 receptor agonists carry an FDA black box warning about the risk of thyroid C-cell tumors based on rodent carcinogenicity data. This risk has not been observed in the extensive human semaglutide and liraglutide datasets, but the regulatory requirement to monitor and report thyroid events means TRIUMPH will accumulate the human thyroid safety data that Phase 2 could not generate.

Pancreatitis rates: Incretin-based drugs have been subject to surveillance for pancreatitis risk since early GLP-1 agonist experience. Large Phase 3 trials generate the denominator needed to characterize absolute pancreatitis rates. Gallbladder events: Rapid weight loss is associated with gallstone formation and gallbladder disease — both semaglutide and tirzepatide Phase 3 data showed modest increases in gallbladder-related events. TRIUMPH will characterize this risk for retatrutide. Bone density: Rapid weight loss is associated with bone density reduction. Phase 3 trials with body composition endpoints will provide data on retatrutide's effects on lean mass and bone density — important questions given the magnitude of weight reduction expected.

The SURMOUNT Phase 3 program for tirzepatide (Eli Lilly's previously approved dual GLP-1/GIP agonist) provides the most direct template for understanding TRIUMPH, since both are Lilly programs and the metabolic indication overlaps substantially.

SUMROUNT-1 (non-diabetic obesity): 2,539 participants, 72 weeks, primary endpoint ≥5% weight loss and percent change from baseline. These are the same primary endpoints planned for TRIUMPH-1. The sample size increase from Phase 2 (338) to SURMOUNT-1 (2,539) is approximately 7.5-fold — a typical Phase 2 to Phase 3 ratio for obesity drug development.

SUMROUNT-2 (T2DM obesity): 938 participants, 72 weeks, co-primary endpoints of weight loss and HbA1c reduction. The T2DM obesity co-primary endpoint structure is also mirrored in TRIUMPH-2.

The SURMOUNT design experience is directly informative for TRIUMPH because the trials are structurally similar. SURMOUNT-1 showed 20.9% mean weight loss at 72 weeks — confirming and slightly exceeding Phase 2 estimates. TRIUMPH-1 data will show whether retatrutide's Phase 3 confirmation tracks Phase 2 data as faithfully as tirzepatide's did. The key scientific question is whether the triple agonism mechanism proves as robust in the larger, more diverse Phase 3 population as it did in the focused Phase 2 cohort.

Phase 3 trials for drugs of this class typically take 2-4 years from initiation to primary completion — meaning TRIUMPH primary data is not expected before 2027-2028. During this period, retatrutide continues to be studied in research contexts that do not require regulatory data.

For preclinical researchers, the Phase 2 data provides the most precise published characterization of retatrutide's pharmacokinetics and dose-response in humans, which can inform animal model dosing decisions and mechanistic hypothesis generation. The triple agonism mechanism — specifically the incremental contribution of glucagon receptor agonism to the GLP-1/GIP baseline — remains an active research question that preclinical models can address in ways that clinical trials cannot.

For researchers studying the metabolic syndrome, insulin resistance, and obesity biology, retatrutide's unique receptor profile makes it a valuable tool for dissecting receptor-specific contributions to energy homeostasis. Comparing retatrutide outcomes to semaglutide and tirzepatide in parallel preclinical experiments provides a systematic framework for mechanistic attribution that the sequential clinical trial record cannot offer.

All research use of retatrutide is for preclinical and research purposes only. Retatrutide is not approved by any regulatory authority and is available exclusively for in vitro and animal model research through research compound suppliers.